The Conversation (0)
Oncolytics Biotech released their financial results for the first quarter of 2017.
Oncolytics Biotech (TSX:ONC, OTCQX:ONCYF) released their financial results for the first quarter of 2017.
As quoted in the press release:
“The last six months – particularly defining our clinical development plan and data announced at AACR – have been exciting for us,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “The compelling and statistically significant overall survival data from the IND 213 study in metastatic breast cancer presented at AACR led us to select this indication as our registration pathway. This is part of our broader clinical development plan, which is focused on exploiting REOLYSIN’s mechanism of action incorporating both cancer cell lysis and immune system priming and activation.”
Click here to read the full press release.
Source: www.newswire.ca